Drug intelligence / Profile preview

[177Lu]Lu-DOTA-PN983

Development stage
Preclinical
Lead developer
SciLifeLab
Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals, Small Molecules
Administration
Intravenous
01

Overview

[177Lu]Lu-DOTA-PN983 is a novel radiolabeled small molecule antagonist targeting the neurokinin-1 receptor (NK1R), developed by researchers at Uppsala University and the Science for Life Laboratory (SciLifeLab) in Sweden. The compound consists of the NK1R-targeting phenylpiperidine-based ligand PN983 conjugated to the chelator DOTA and radiolabeled with the beta-emitting radionuclide lutetium-177 (177Lu). NK1R is a G-protein coupled receptor that is overexpressed in several malignancies, including glioblastoma, neuroblastoma, and breast cancer. In preclinical studies, [177Lu]Lu-DOTA-PN983 demonstrated high binding affinity to NK1R (KD = 4 nM) and favorable in vivo biodistribution, showing rapid tumor uptake and high tumor-to-blood ratios, making it a promising candidate for targeted radionuclide therapy and SPECT/CT imaging of NK1R-positive tumors.

Other names
[177Lu]-DOTA-PN983[¹⁷⁷Lu]Lu-DOTA-PN983
02

Identity

Drug type
Peptides
Modality
Small MoleculesAntibody-Based TherapeuticsAntibody-Radionuclide ConjugatesBeta-minus EmittersGamma Emitters
Synonyms and codes
DOTA-PN983PN983
03

Pharmacology

Route
Intravenous
04

Development

IndicationHighest phaseStatus
breast cancer and precursor lesionsPreclinicalActive
glioblastoma, IDH-wildtypePreclinicalActive
neuroblastomaPreclinicalActive
neuroblastoma (MYCN-amplified / non-amplified)PreclinicalActive

Every indication, with countries and timelines, is in the full profile.

05

Regulatory

MarketStatusYear
United StatesNot approved—
European UnionNot approved—
ChinaNot approved—
JapanNot approved—

Approved indications and other markets are in the full profile.

06

Companies

  • SciLifeLabLead developer
07

Competitive landscape

Drugs on the same target
35
Drugs in the lead indication
1,053

Lead indication: breast cancer and precursor lesions

Most advanced in the lead indication

  1. cyclophosphamideApproved
  2. epirubicinApproved
  3. eribulinApproved
  4. fludeoxyglucose f 18Approved
  5. fluorouracilApproved

Beyond the preview

Go deeper on [177Lu]Lu-DOTA-PN983.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on [177Lu]Lu-DOTA-PN983.

Work on [177Lu]Lu-DOTA-PN983? Claim this page to correct or add information. Claim this page

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call